氯米帕明联合利培酮治疗强迫症疗效观察.docVIP

氯米帕明联合利培酮治疗强迫症疗效观察 　　【摘要】目的:探讨氯米帕明联合利培酮治疗强迫症的临床疗效。方法:将60例强迫症患者随机分为观察组和对照组各30例,观察组采用氯米帕明联合利培酮治疗,对照组采用氯丙嗪治疗,于治疗前及治疗10w末采用强迫症量表、恐怖/强迫量表、汉密顿焦虑量表评定疗效,副反应量表评定不良反应。结果:治疗10w末观察组痊愈观察组患者痊愈11例,显效14例,有效5例,总有效率为100%;对照组痊愈5例,显效10例,有效8例,无效7例,总有效率为76.67%;经统计学分析,观察组疗效显著优于对照组(P＜0.05)。各量表评分治疗10w末两组均较治疗前有显著下降(P＜0.01),但研究组均较对照组下降显著(P＜0.01)。结论:氯米帕明联合利培酮治疗强迫症临床疗效显著,安全性高,依从性好,值得临床应用推广。 　　【关键词】氯米帕明;利培酮;强迫症 　　 　　Clinical effect of chlorimipramine and nikethamide on patients of obsessive compulsive disorderXIE Zhong 　　【Abstract】Objective: To explore the clinical curative effect and safety of chlorimipramine and nikethamide on patients of obsessive-compulsive disorder.Methods:60 patients of obsessive compulsive disorder were divided randomly into the intervention group (30 cases) and the control group (30 cases), the intervention group was chlorimipramine and nikethamide for 10 weeks, while the control group was treated with chlorpromazine for 10 weeks, Clinical efficacies were assessed with the Y BOCS、MSCPOR and HAMA and adverse reactions with the Treatment Emergent Symptom Scale(TESS) before and after treatment．Results: After 10 week treatment, total effectiveness rate was 100% in the intervention group,76.67% in the control group，which showed that the former were better than the latter(P＜0.05). Scores of all scales lowered more significantly after treatment compared with pre treatment in both two groups(P＜0.01), and those did more significantly in the research than in the control(P＜0.01).Conclusions：chlorimipramine and nikethamide is evident effective and higher safe for the treatment of patients of obsessive-compulsive disorder, and hence is worthy of being recommended in clinical practice. 　　【Key words】Chlorimipramine;Nikethamide;Obsessive compulsive disorder 　　【中图分类号】R971+.41 【文献标识码】A 【文章编号】1006-1959（2009）06-0011-02 　　 　　强迫症是以反复出现强迫观念或行为为基本特征的一类神经症性障碍,目前关于强迫症的发病机制仍不完全清楚,临床治疗比较棘手。2006年1月～2008年1月期间我们采用氯米帕明联合利培酮治疗强迫症,效果满意,现报道如下。 　　 　　1 资料和方法 　　 　　1.1 一般资料:60例强迫症患者中男23例,女57例,年龄